INTRODUCTION
Arterial and venous blood vessels are anatomically, functionally, and molecularly distinct. Establishing and maintaining these separate endothelial cell fates is critical to the proper function of circulatory networks in the embryo and the mature adult (Marchuk, 1998) . Angioblasts are specified in the lateral plate mesoderm during gastrulation. Bilateral streaks of vascular endothelial growth factor receptor 2 (VEGFR2)/Flk1 + -preaortic angioblasts, or arterial precursor cells (aPCs), form the dorsal aortae, followed by the formation of the embryonic veins by a distinct group of angioblasts (Chong et al., 2011) . Arteriovenous (AV) specification is genetically determined before hemodynamic forces come into play. Hedgehog (Hh) signaling induces expression of Vegf in a dorsal to ventral gradient in the early embryo (Lawson et al., 2002) . Arterial cells are thought to receive a higher concentration of Vegf, which activates p42/p44 MAPK signaling (Hong et al., 2006) and induces the expression and activation of Notch signaling pathway components exclusively in the arterial endothelium (Lawson et al., 2002) . Once activated, the intracellular domain of the cleaved Notch receptor (NICD) interacts with its transcriptional cofactor, RBPJk, in the nucleus to induce expression of Hey1/2, Hes1, EphrinB2 (Efnb2), and other downstream arterial genes (Yamamizu et al., 2010) . The molecular events following Notch activation that maintain arterial identity are well understood (Swift and Weinstein, 2009 ), yet the initial transcriptional cues that function downstream of Vegf activation to induce the expression of Notch signaling components are unknown.
Dll4 is the first Notch ligand gene expressed in the arterial endothelium (Chong et al., 2011) , and its expression is induced by Vegf (Lawson et al., 2001) . Expression of Dll4 is initiated in the dorsal aorta before genes encoding its cognate receptors, Notch1 and Notch4, making Dll4 one of the earliest markers of the arterial lineage (Chong et al., 2011) . Significantly, loss of only one copy of Dll4 produces AV specification defects and embryonic lethality in mice Gale et al., 2004; Krebs et al., 2004) . Defining the transcriptional program responsible for early Dll4 expression will therefore provide key insights into arterial specification.
We describe the isolation of an arterial-specific enhancer of Dll4, which labels aPCs and differentiated arterial cells. We find that this enhancer is responsive to Vegf/MAPK signaling, and, through deletion analysis, we identify a previously unappreciated role for ETS transcription factors in mediating the 
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Vegf-responsiveness and arterial-specificity of this enhancer and endogenous Dll4. This Vegf/MAPK/ETS pathway also regulates the expression of Notch4, which encodes an arterialspecific receptor of Dll4. These studies provide mechanistic insight into the transcriptional program downstream of the Vegf receptor that mediates arterial specification through the induction of Notch signaling components.
RESULTS
The Genomic Region 5 0 of Dll4 Does Not Drive ArterialSpecific Expression To understand the transcriptional basis of AV specification, we searched for evolutionarily conserved noncoding regions (ECRs) of the Dll4 locus. The region proximal to the Dll4 transcriptional start-site is regulated by b-catenin signaling through TCF/LEF sites and can also be activated by FOXC1/2 and RBPJk in vitro (Caolo et al., 2010; Corada et al., 2010; Seo et al., 2006) . We cloned this 5-kb region (fragment 1, F1) and placed it upstream of a promoterless b-galactosidase reporter ( Figure 1A ; see also Figure S1A available online). The activity of this reporter construct was tested in transient transgenic mouse embryos, where it failed to direct any arterial expression (Figures 1A, S1A, and S1B). This suggests that this region is not sufficient to mediate the arterial-specific expression of Dll4.
Wnt Signaling Is Not Required for Early Dll4 Expression or Artery Specification
Endothelial-specific deletion of Ctnnb1, the gene encoding b-catenin, results in embryonic lethality at E12.5 (Cattelino et al., 2003) . However, whether AV specification occurs normally in Ctnnb1 loss-of-function mice has not been previously assessed. Overexpression of a dominant-active allele of Ctnnb1 induces Dll4 expression (Corada et al., 2010) , leading to the suggestion that Wnt/b-catenin plays an instructive role in arterial specification by inducing Notch signaling. However, we were unable to detect active canonical Wnt signaling in the arterial endothelium at E8.5 or E9.5 using multiple established Wnt reporter lines Axin2 lacZ ) (Figures S1C-S1E). To determine if Wnt signaling regulates early Dll4 expression, we ablated Ctnnb1 specifically in the endothelium. The dorsal aortae and cardinal vein were morphologically normal at E8.5 (data not shown) and E9.5 ( Figure S1F ), expression of Dll4 mRNA was unchanged (Figure S1G) , and we did not observe any arteriovenous malformations (AVMs) in Ctnnb1 mutants at E9.5 ( Figure S1H ).
Collectively, these results demonstrate that Wnt/b-catenin signaling in the endothelium is dispensable for early artery formation and early Dll4 expression and that the DNA region upstream of the promoter of Dll4 is not sufficient for artery-specific expression.
Identification of a Dll4 Enhancer with Activity in the Developing Arterial Endothelium and Endocardium
Another well-conserved ECR (fragment 2, F2) is located within the third intron of Dll4 ( Figure 1A ). This region can respond to FOXN4 (Luo et al., 2012) , RBPJk/NICD, and b-catenin (Yamamizu et al., 2010) in both ex-vivo and in vitro reporter analyses, but its in vivo activity has not been assessed. In transient transgenic embryos, F2 drove robust activation of a minimal promoter-lacZ reporter (hsp68-lacZ) in the arterial endothelium and endocardium, similar to endogenous Dll4 mRNA expression and to the b-galactosidase activity of Dll4 lacZ/+ embryos (Figure 1B) . Analysis of embryos at E7.5-E7.75 from multiple stable transgenic founder lines demonstrated that this enhancer labeled aPCs prior to their coalescence into the cord-like structures of the dorsal aorta ( Figures 1B and 1C) . Examination of transverse sections confirmed the arterial-specificity of the enhancer from E8.5 through E10.5 ( Figure 1D ). F2 also drove strong expression in the endocardium, another tissue where Dll4 mRNA is observed (Figure 1B) , suggesting that this enhancer recapitulates the entire developmental endothelial expression pattern of endogenous Dll4. F2, like endogenous Dll4, was active in the arteries of the postnatal retina, but it was not active in the vasculature of the adult retina, suggesting that F2 is a developmentally regulated enhancer (data not shown). To determine whether this enhancer's functionality was conserved in other vertebrate species, we injected an F2:GFP transgene into zebrafish embryos and established stable transgenic lines. Expression of GFP was specific to the dorsal aorta, cardinal artery, and intersomitic vessels, with very little expression detectable in the posterior cardinal vein or caudal vein plexus ( Figures 1E and 1F ). This intronic Dll4 F2 element is therefore a bona fide arterial-specific enhancer.
A 36 bp Fragment Necessary and Sufficient for Arterial-Specific Enhancer Activity Is Regulated by ETS and RBPJk Comparative genomic analysis revealed that the full-length F2 enhancer contains regions of high conservation among distantly related mammals (Figure 2A ). Using deletion analyses of the 802 bp F2 enhancer, we identified a 350 bp (F2-2) and a 225 bp fragment (F2-4) that both labeled the arterial endothelium, as well as a weak endocardial enhancer (F2-3) that failed to label the arterial endothelium in mice (Figures 2A and 2B) . The proximal 176 bp of the F2 enhancer (F2-5), which is contained in F2 and F2-2, but absent in F2-4, was not sufficient to drive arterial expression (Figures 2A and 2B ). F2, F2-2, and F2-4 share a common 100 bp region that, when deleted in the context of the entire 802 bp enhancer (F2D1), abolished arterial activity (Figures 2A and 2B) . A well-conserved 36 bp element within this common region was necessary (F2D2) and, when concatamerized head-to-tail in triplicate (F2-6(3X)), was sufficient to direct arterial and endocardial expression ( Figures  2A-2C ). Further characterization revealed that this minimal (B) Representative transgenic embryos from (A) at E9.5. F2, F2-2, and F2-4 directed strong arterial-specific expression. F2-3 directed weak endocardial (EC) expression. Deletion of a highly conserved 100 bp and 36 bp region (F2D1 and F2D2, respectively) abrogated arterial activity of the F2 enhancer. The 36 bp region, F2-6, was sufficient, when arrayed in triplicate, F2-6(3X), to direct arterial expression. DA, dorsal aorta; AA, aortic arch; LB, limb bud; NT, neural tube; ICA, internal cerebral artery; HT, heart. Scale bar represents 500 mm.
(C) Transverse section of X-gal stained F2-6(3X)-lacZ embryo at E9.5. DA (arrow); cardinal vein (caret); EC (double arrow). Scale bar represents 100 mm.
(D) Whole-mount image of F2-6(3X)-lacZ embryo at E8.5. Scale bar represents 500 mm.
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Developmental Cell ETS Factors Regulate Arterial Specification 36 bp enhancer (F2-6(3X)) was capable of directing robust and reproducible arterial expression at early stages (i.e., E8.5) of vascular development ( Figure 2D ). Importantly, transient transgenesis revealed that this 36 bp enhancer was also able to drive strong arterial-specific expression in the dorsal aorta and intersomitic vessels (Figure 2E) , as well as the endocardium (data not shown), of zebrafish embryos. Venous expression was not observed in embryonic mice or zebrafish ( Figures 2C and 2E ). The minimal enhancer contains conserved predicted binding sites for ETS, MEF2, E2F, and RBPJk transcription factors (Figure 2F) . We tested which sites were required for activity in vivo by separately mutating each DNA-binding site in the context of the F2-6(3X):GFP reporter and performing transient transgenesis assays in embryonic zebrafish. At 24 hr postfertilization (hpf), $75% of embryos injected with the wild-type F2-6(3X) enhancer displayed arterial expression of GFP. Mutation of the E2F element did not affect enhancer activity, but mutation of the MEF2 element resulted in a modest, but significant reduction in arterial expression ( Figure 2G ). In mice, Mef2a and Mef2c are expressed within the endothelium (Lin et al., 1998; Wang et al., 2003) and loss of Mef2c leads to early embryonic lethality ($E9.5) and produces a range of vascular defects, including an absent or disorganized dorsal aorta (Bi et al., 1999; Lin et al., 1998) . Although recombinant MEF2C protein bound to the MEF2 site of F2-6(3X) (Figure S2A ), MEF2C was not required for either F2 activity or endogenous Dll4 expression ( Figures  S2B and S2C) . Conversely, only 5% of zebrafish embryos injected with an ETS mutant F2-6(3X):GFP construct had arterial expression and mutation of the RBPJk-binding site abolished arterial expression ( Figure 2G ). These results suggest that ETS and RBPJk play a critical role in regulating F2-6(3X) enhancer activity in vivo and imply that they may regulate endogenous Dll4.
Neither the RBPJk Site in the F2 Full-Length Enhancer nor Notch Signaling Are Required for Initiation of Dll4 Expression It has been proposed that activated Notch signaling can induce Dll4 gene expression via RBPJk-mediated transcriptional regulation through a feed-forward mechanism (Caolo et al., 2010) . Given that the activity of the minimal F2-6(3X) enhancer was dependent upon a putative RBPJk-binding site, we sought to determine if Notch signaling is necessary or sufficient to regulate the activity of the full-length F2 enhancer. Forced induction of Notch signaling throughout the vasculature promotes the arterialization of veins (Krebs et al., 2010) . Indeed, endothelial-specific overexpression of the intracellular domain of Notch1 produced AVMs in mouse embryos and expanded F2 reporter activity into the venous endothelium ( Figure S2D ), suggesting that the enhancer is Notch responsive. However, although RBPJk bound to the F2 enhancer ( Figure S2E ), mutation of the RBPJk site in the context of the fulllength F2 enhancer failed to diminish arterial-specific expression in transient transgenesis analyses in zebrafish or mice (Figures 3A and 3B) . We next assessed whether Notch signaling is required for F2 enhancer activity. Rbpjk knockdown in zebrafish reduced late (i.e., 26 hpf), but not early (i.e., 20 somites) enhancer activity (Figure 3C ), consistent with a role for Notch signaling in the maintenance, but not the establishment of arterial Dll4 enhancer activity. In mice, global loss of Rbpjk, which leads to defects in somitogenesis and neural tube formation (Oka et al., 1995) , diminished but failed to abolish F2 reporter activity at E8.25 or E8.5 ( Figure 3D ). Additionally, in embryos where Rbpjk was ablated specifically in the endothelium-bypassing global morphogenetic defectsthe activity of the F2 reporter was unaffected at E8.5 or E9.5 (Figure 3E) , demonstrating that RBPJk does not play a cell-autonomous role in initiating Dll4 enhancer activity. Finally, Dll4 mRNA was only moderately reduced in Rbpjk À/À mice compared to wild-type littermates at E8.5 ( Figure 3F ). Together, these results indicate that Notch signaling is not required for the early arterial expression of Dll4, but is essential for its maintenance.
ETS Factors Regulate the Activity of the Dll4 Enhancer
ClustalW analysis revealed the presence of nine perfectly conserved minimal ETS elements (ETS sites A-G), including the site within F2-6(3X) (ETS-B) ( Figure S3A ). This was intriguing because several ETS family members are key regulators of endothelial development (De Val and Black, 2009) . EMSA confirmed that six of these sites competed for binding of the ETS1 DNA binding domain (DBD) to a known ETS element (Figure S3B) . Among these six sites, ETS-B is present in all arterialpositive constructs (F2, F2-2, F2-4, and F2-6) and corresponds to a canonical ETS-1 binding site (cETS-1). ETS-B also directly and specifically bound recombinant ETS1-DBD ( Figure S3C ) and ETV2, an ETS family member ( Figure S3D ). To determine the functional requirement of the ETS binding sites in vivo, we generated transient transgenic zebrafish harboring the full-length F2 enhancer driving GFP in which ETS-B or all six of the ETS1 DBD-binding ETS sites were mutated. Mutation of the six ETS binding sites abolished F2 enhancer activity, and mutation of the ETS-B site alone severely reduced enhancer activity in arteries ( Figure 4A) ; confirming the importance of this single ETS element. Given the necessity of ETS binding sites for enhancer activity, we wondered whether ETS factors were sufficient to induce Dll4 expression. Thus, we next determined whether overexpression of ETS factors was sufficient to induce expression of endogenous DLL4 in human umbilical vein endothelial cells (HUVEC), a venous cell type that expresses low levels of DLL4. Indeed, overexpression of two different endothelial-enriched ETS family members, ETV2 or ERG, induced endogenous DLL4 expression ( Figure 4B ). Induction of DLL4 was accompanied by binding of V5-ERG to the endogenous region of DLL4 corresponding to F2 (i.e., intron 3), but not to a distal region of the DLL4 locus, as assessed See also Figure S2 .
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by chromatin immunoprecipitation (ChIP) ( Figure 4C ). Furthermore, we detected high levels of endogenous ERG occupancy at intron 3, but not a distal site in the Dll4 locus, in an arterial cell line (bovine aortic endothelial cells [BAECs]) ( Figure 4D ). By comparison, NICD was only modestly enriched at intron 3 in BAECs ( Figure 4D ). Collectively, these results demonstrate that ETS factors can induce expression of endogenous DLL4 mRNA and that ETS factors directly occupy the endogenous DLL4 genomic region corresponding to F2 in arterial cells.
To further define the role of ETS factors in the regulation of Dll4 expression, we performed loss-and gain-of-function experi- , n = 4). (E) F2-lacZ expression was normal at E8.5 (left), and at E9.5 in whole-mount (center) and transverse sections (right) from embryos with endothelial cell-specific loss (ECKO) of Rbpjk, although mutants had a reduced DA diameter (bar) at E9.5, as previously reported (Krebs et al., 2004) . E9.5,
In situ hybridization shows that Rbpjk is not absolutely required for Dll4 expression at E8.5 (n = 3 for each genotype). DA, arrows; asterisk, neural tube. Scale bars represent 50 mm (A and C), 500 mm for whole-mounts, and 100 mm for sections (B and D-F) . See also Figure S2 . ments in mouse and zebrafish. Fli1a and Erg are closely related ETS factors that play redundant roles in regulating angiogenesis during zebrafish vascular development . Combined morpholino knockdown of these two ETS factors decreased F2:GFP expression at both early and late stages of vascular development (Figure 4E) , and endogenous dll4, efnb2a, and hey2 expression were also diminished ( Figure 4F ). However, kdrl:GFP expression (a pan-endothelial marker) was unaffected (Figure 4E) , as was kdr mRNA ( Figure 4F ). Conversely, injection of ERG mRNA increased F2:GFP expression within the dorsal aorta and in what appeared to be the forming posterior cardinal vein at early stages of arterial specification (i.e., 20 somite stage), and also promoted premature sprouting of intersomitic vessels ( Figure S4A ). However, expanded enhancer activity in the vein was not observed at later stages of vascular development (i.e., 24 hpf; not shown). Because Notch target genes (i.e., efnb2a, hey2) were decreased in erg/fli1a morphants, we assessed Notch transcriptional activity using a Notch reporter line (Tp1:GFP) (Parsons et al., 2009) in an erg/fli1a lossof-function setting. Strong Tp1:GFP expression in the dorsal aorta and intersomitic vessels was observed in 94% of control Developmental Cell ETS Factors Regulate Arterial Specification embryos (n = 83) compared to only 67% of erg/fli1a morphants (n = 165), suggesting that arterial Notch signaling was compromised in a proportion of ETS morphants (Figure 4G) .
Erg splice variants in mice, driven from a translational start site in Exon 4, are specifically expressed in the endothelium, and Erg Exon 4 null mouse embryos (Erg DEx4/DEx4 ) die early in development (E10.5-E11.5) with severe vascular remodeling defects in the yolk sac and impaired vascularization of the central nervous system . We found that the dorsal aortae formed normally in Erg DEx4/DEx4 embryos ( Figure S4B ), but Dll4 expression was modestly reduced at E8.5 ( Figure 4H ) and substantially downregulated at E9.5 ( Figure 4I ), confirming a role for this ETS family member in regulating Dll4 mRNA expression. Interestingly, several other arterial markers were also reduced in Erg DEx4/DEx4 embryos at E8.5 ( Figure 4H ), and levels of Efnb2
were modestly reduced at E8.5 ( Figures 4H and S4C ) and E9.5 ( Figure 4J ), but were severely altered at E10.5 (data not shown). However, we did not find evidence of gross morphological AVM defects in Erg DEx4/DEx4 embryos at E9.5 (Figures S4B and S4D) and only rarely observed shunts in erg/fli1a morphant zebrafish embryos (data not shown). We take these results to indicate that ETS factor redundancy may functionally compensate for the loss of ERG or Erg/Fli1a within the endothelium. Together these data define a role for ETS factors in the regulation of the arterial-specific expression of Dll4 and indicate that ETS factors are involved in the specification of arterial fate.
Vegf Signaling Regulates the Expression of Dll4 through the Induction and Activation of ETS Factors
Arterial specification is largely Hh-and Vegf-dependent (Lawson et al., 2002; Vokes et al., 2004) , and Dll4 expression is regulated by Vegf levels (Coultas et al., 2010; Liu et al., 2003) . We therefore assessed whether F2 enhancer activity was Vegf-responsive. vegfa knockdown in zebrafish dramatically reduced F2 arterial enhancer activity ( Figures 5A and 5B), similar to endogenous dll4 mRNA ( Figure 5C ). However, the expression of a pan-endothelial marker (kdrl:GFP) in the axial vessels and levels of kdr and kdrl mRNA were largely unaffected (Figures 5A-5C), confirming that vegfa does not regulate vasculogenesis in zebrafish. Global overexpression of Vegfa, achieved by coinjection of mRNAs encoding Vegfa 121 and Vegfa 165 , dramatically increased F2 activity in arterial cells ( Figure 5D ). In addition, F2 activity was expanded into the vein, confirming that Vegf levels regulate the arterial-specific expression of Dll4. Additionally, we examined F2-lacZ activity in two mutant mouse backgrounds that affect Vegf signaling. Hh-mediated activation of Smoothened (SMO) is required for expression of Vegf in the rostral somites at E8.5 and loss of Smo leads to disorganized or collapsed anterior (but not posterior) dorsal aortae by E8.5; although Flk1 + cells are specified and present in normal numbers (Vokes et al., 2004) . Significantly, Smo mutants have reduced Dll4 mRNA in the anterior, but not posterior, dorsal aorta at E8.5 (Coultas et al., 2010) . Correspondingly, we found that F2 enhancer activity was reduced in the anterior, but not the posterior dorsal aorta of Smo mutants at E8.25, and activity was abolished in this region of the dorsal aorta by E8.5 ( Figure S5A ). Additionally, enhancer activity was absent in Vegfr2 À/À embryos ( Figure S5A ), although this is likely the result of reduced vasculogenesis (Shalaby et al., 1995).
To determine which cis elements within F2 mediate this Vegf responsiveness, we performed luciferase assays in cultured arterial endothelial cells treated with VEGF or the VEGF receptor inhibitor, SU5416. Endogenous DLL4 mRNA was elevated in cells treated with VEGF compared to cells treated with SU5416 ( Figure 5E ). Although wild-type F2-luciferase activity was enhanced upon VEGF-treatment, mutation of ETS-B abrogated Vegf responsiveness and this reduction was only slightly more pronounced in the ETS-6x mutant ( Figure 5F ). Although mutation of the RBPJk site modestly reduced enhancer activity, this reduction was not as severe as mutation of the ETS elements. This suggests that the Vegf responsiveness of the Dll4 enhancer is largely ETS-dependent.
Control of ETS activity by Vegf signaling could be mediated by alterations in the expression and/or activity of ETS factors. We first assessed whether the recruitment of ETS factors to the enhancer at the endogenous DLL4 locus was dependent on Vegf signaling. RNA Polymerase II occupancy at the DLL4 enhancer in cultured arterial cells was enhanced in VEGF-treated cells compared to cells treated with VEGF inhibitor (Figure 5G ), a finding consistent with transcriptional regulation of DLL4. Importantly, ERG occupancy of the enhancer was also increased in the presence of Vegf signaling ( Figure 5G ). However, Vegf treatment did not alter ERG protein levels ( Figure 5H ), or ERG subcellular localization in arterial cells ( Figures 5I and S5B) . Interestingly, ERG protein levels were elevated in lysates from cells of arterial origin (human umbilical artery endothelial cells [HUAEC] ) compared to corresponding venous cells (HUVEC) (Figure 5J) , and expression of ERG was moderately enriched in the dorsal aorta compared to the cardinal vein in vivo (Figure S5C) , suggesting that ERG is enriched in arterial cells. Although ERG levels were not affected by short-term inhibition of Vegf signaling in cultured arterial cells, the expression of several ETS factors are Vegfresponsive in vitro (Ghosh et al., 2012; Heo et al., 2010) . Therefore, we examined the levels of endothelial-enriched ETS factors to determine whether Vegf regulated their expression during vascular development. Compared to controls, quantitative RT-PCR (qRT-PCR) analyses revealed that levels of elf2a, elf2b, elk4, erg, ets1a, and fli1a were significantly reduced in vegfa morphants ( Figures S5D and S5E ). In contrast, the expression of etv2, which acts early in the gastrulation-stage mesoderm to specify endothelial cells (Lee et al., 2008) , was unaffected by Vegf inhibition (Figures S5D and S5E) . Thus, expression of several endothelial ETS factors is modulated by Vegf signaling in vivo, and their decreased expression coincides with a reduction in dll4 expression.
To determine if ETS factors function downstream of Vegf signaling to induce Dll4 expression, we overexpressed ERG in vegfa morphants. Coinjection of ERG mRNA partially rescued Dll4 F2 enhancer activity, sprouting of ISVs, and endogenous dll4 expression in vegfa morphant embryos ( Figures 6A and 6B ). Interestingly, F2 enhancer activity was expanded into the vein in ERG overexpressing vegfa morphants. Conversely, knockdown of erg and fli1a (using a subphenotypic dose of morpholino) prevented the Vegf-mediated induction of F2:GFP in both the artery and the vein ( Figure 6C ). Increased expression of endogenous dll4 ( Figure 6D ) and efnb2a (Figure S6A specification, respectively (Deng et al., 2013; Hong et al., 2006; Ren et al., 2010) . Pharmacological inhibition of p42/p44 MAPK signaling in arterial cells in vitro decreased DLL4 expression (Figure 7A ). An arterial-enriched Notch receptor gene, NOTCH4, was also reduced, but NOTCH1 and venous gene expression (EPHB4 and COUP-TFII), were unchanged ( Figure 7A ). Consistent with decreased Notch ligand (i.e., DLL4) and receptor (i.e., NOTCH4) levels, expression of a Notch-activated transcription factor gene, HES1, and a Notch-dependent arterial marker, EFNB2, were also reduced ( Figure 7A ). These data suggest that MAPK signaling is required for the maintenance of Notch signaling in arterial endothelium. In contrast, inhibition of PI3K Developmental Cell ETS Factors Regulate Arterial Specification activity with the small molecule, LY29004, enhanced expression of DLL4, NOTCH4, HES1, and EFNB2 (data not shown). Because NOTCH4 was regulated similarly to DLL4, we examined ECRs within the NOTCH4 locus for conserved ETS elements. An ECR within intron 1 of NOTCH4 contained multiple conserved ETS sites, and this region had high ERG occupancy in arterial cells, as assessed by ChIP ( Figure 7B ). Overexpression of ERG in HUVEC induced NOTCH4 mRNA, suggesting that NOTCH4 is an ETS factor-regulated gene ( Figure 7C ). Similar to DLL4, NOTCH4 expression was downregulated upon Vegf inhibition (Figure 7D) , and this was accompanied by a decrease in ERG recruitment to intron 1 ( Figure 7E ). We also found that ERG recruitment to DLL4 intron 3 and NOTCH4 intron 1 was reduced in cells treated with a MAPK inhibitor (Figure 7F ), suggesting that ERG recruitment to these enhancers is MAPK-dependent. Accordingly, Vegf-induced Dll4 F2-luciferase activity was suppressed by MAPK inhibition in arterial cells and mutation of the ETS-B site largely abrogated this responsiveness ( Figure 7G ). In contrast, inhibition of PI3K signaling enhanced Vegf-induction of F2-luciferase activity, and this was also dependent on the ETS-B site (Figure S6B) , suggesting that PI3K inhibition may enhance ETS activity. To determine whether MAPK regulates Dll4 in vivo, we inhibited MAPK signaling beginning at the 10-somite stage and found a significant decrease in F2:GFP expression at 28 hpf ( Figures S6C and S6D) . Expression of endogenous dll4 and hey2 mRNA was also reduced, whereas efnb2a levels were modestly decreased ( Figure S6E ). However, kdrl:GFP and kdr expression were unaffected ( Figures S6D and S6E) . In agreement with the MAPK inhibitor data, overexpression of dominant active MEKK in endothelial cells resulted in ectopic expression of F2:GFP within venous cells in vivo (Figure S6F ), implying a cell- autonomous role for MAPK signaling in the regulation of arterial Dll4 expression.
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DISCUSSION
Hh/Vegf-dependent activation of Dll4 expression and Notch/RBPJk activity is a prerequisite for early artery specification and maintenance in the developing vertebrate embryo (Swift and Weinstein, 2009 ). The MAPK pathway activates the arterial program downstream of VEGFR2, whereas PI3K signaling antagonizes the MAPK pathway and arterial fate (Deng et al., 2013; Hong et al., 2006; Ren et al., 2010) . However, the transcriptional mediators that are activated downstream of VEGFR2/MAPK and induce Dll4 expression, and hence Notch activation, remain unknown. Here, we report the identification of an arterial-specific enhancer (F2) of Dll4, one of the earliest markers of the coalescing aPCs that form the dorsal aortae. The activity of the Dll4 F2 enhancer described here recapitulates endogenous Dll4 expression in the arterial and endocardial endothelium of the developing embryo. Functional analysis of this enhancer reveals that a minimal 36 bp DNA element, when concatenated, can drive arterial-specific expression, and through systematic mutation of the cis elements in this enhancer, we identify a role for the ETS family of transcription factors in the Vegf-and MAPK-dependent initiation of Dll4 expression ( Figure 7H ). Critically, Notch4 is also regulated by this Vegf/MAPK/ETS pathway, suggesting that this genetic network may coordinately activate expression of Notch signaling components to initiate Notch signaling in the early artery.
Previous work implicated FOXC1/2 and b-catenin in the regulation of Dll4 expression (Corada et al., 2010; Seo et al., 2006; Yamamizu et al., 2010) . However, our results argue against these factors directing the arterial-specific expression of Dll4. In the case of Foxc1/2-dependent regulation of Dll4, the conclusions rely largely upon the phenotype of Foxc1 
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Vegf that is required for artery specification (Coultas et al., 2010) . Similarly, although prior studies suggested that canonical Wnt/ b-catenin signaling is active in early arteries (i.e., E9.5) and b-catenin drives Dll4 promoter activity (Corada et al., 2010) , we find no evidence of active canonical Wnt/b-catenin signaling in early arteries (i.e., E8.5 and E9.5) and Dll4 expression in the dorsal aorta is intact when Ctnnb1 is deleted from the endothelium, suggesting that b-catenin is dispensable for early artery specification. Finally, the genomic fragment that is located just upstream of Dll4-where b-catenin/TCF/LEF and Foxc1/2 have been suggested to function-does not direct arterial-specific expression.
Vegf-mediated activation of Notch signaling, via NICD/RBPJk transcriptional activity is necessary and sufficient to induce downstream transcription factors, such as Hey2 and other arterial markers, such as Efnb2 (Swift and Weinstein, 2009) . However, we postulate that Notch signaling is not required for the initiation of Dll4 expression and primitive dorsal aortae formation. Dll4 is the first Notch ligand expressed in the forming arteries in the mouse, and Dll4 expression (first detected at E8.0) precedes that of the genes encoding arterial Notch receptors, Notch1 and Notch4 (detected at E8.25) (Chong et al., 2011) ; calling into question how endothelial cell-autonomous Notch signaling could initiate Dll4 expression. Indeed, Notch1 À/À ;Notch4 À/À mice have normal levels of Dll4 at E9.5 (albeit in an abnormal expression pattern), and the dorsal aortae are still formed (Krebs et al., 2000) . Similarly, dorsal aortae are present when Rbpjk is deleted specifically in the endothelium (Krebs et al., 2004) . Although the arterial enhancer of Dll4 that we isolated (F2) contains a conserved functional binding site for RBPJk, we provide several lines of evidence demonstrating that Notch signaling is not required for the initial arterial expression of Dll4. First, mutation of the RBPJk site in the context of the full-length enhancer does not affect its arterial-specificity in mice or zebrafish embryos. Second, global loss of Rbpjk in embryonic mice or zebrafish fails to abolish enhancer activity early in arterial development. Third, early arterial expression of endogenous Dll4 mRNA is present, albeit at reduced levels, in Rbpjk À/À embryos.
However, endothelial-specific ablation of Notch signaling does not diminish F2 activity at E8.5 or E9.5, suggesting a possible 
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Other Arterial Genes (i.e. Notch4, Hey2, Efnb2) Developmental Cell ETS Factors Regulate Arterial Specification nonendothelial role for Notch signaling in regulating Dll4. Interestingly, Dll4 enhancer activity in the dorsal aorta is greatly reduced in later-stage rbpjk morphant zebrafish embryos, suggesting that Notch signaling maintains Dll4 expression. Collectively, our findings demonstrate that initiation of Dll4 expression during artery specification is Notch-independent. We propose that Dll4 expression is initiated during vasculogenesis (through Notch-independent mechanisms; see below), and that Notch signaling subsequently becomes activated by a Vegf/MAPK/ ETS pathway that regulates both Dll4 and Notch4 ( Figure 7H ). Subsequently, Dll4 expression is maintained through a Notchdependent positive feedback loop to sustain artery specification, as has been previously suggested (Caolo et al., 2010) . A highly conserved ETS site (i.e., ETS-B) is responsible for the majority of the activity of the arterial enhancer of Dll4, including its responsiveness to Vegf/MAPK signaling. How then do ETS factors, many of which are uniformly expressed in the vasculature, regulate the arterial specificity of Dll4? The Dll4 enhancer can be bound ( Figure S3D ) and activated (data not shown) by the angioblast-enriched ETS family member ETV2 (Lee et al., 2008) . Interestingly, the first angioblasts to arise during murine development appear to be arterial (Chong et al., 2011) . We therefore posit that ETV2 initiates Dll4 expression during vasculogenesis ( Figure 7H ). Our data further suggests that a second wave of Vegf-dependent ETS factors appears to reinforce Dll4 expression in the forming dorsal aortae ( Figure 7H ). We find that Vegf regulates the expression of several zebrafish ETS factors in the endothelium, including elf2a, elf2b, elk4, erg, ets1, and fli1a. Furthermore, ERG appears to be enriched in arterial cells, implying that some ETS factors may be arterial-enriched. More importantly, we discover that the recruitment of ERG to the Dll4 F2 enhancer and an ECR within Notch4 is induced by Vegf/MAPK signaling. In this case, differential ERG occupancy is not mediated by changes in total ERG levels or subcellular localization, suggesting that Vegf/MAPK signaling enhances the DNA binding activity of ERG. We have also observed Vegfdependent recruitment of ETS1 to these same enhancers (unpublished results mined from data in Zhang et al., 2013) , suggesting that additional ETS family members may be regulated similarly to ERG, and cooperatively control arterial specification. Importantly, the enhanced activation of the Dll4 enhancer and endogenous dll4 in response to vegfa overexpression can be attenuated by knockdown of erg and fli1a, suggesting that ETS factors are necessary for the Vegf-induced expression of Dll4. We also find reduced Dll4 expression in the dorsal aorta of Erg DEx4/DEx4 mice and in erg/fli1a morphant zebrafish embryos, but failed to observe AVMs, suggesting that other ETS factors compensate in the specification of the early artery. Vegf is known to selectively activate MAPK signaling in arteries compared to veins during embryogenesis (Corson et al., 2003; Hong et al., 2006) . Interestingly, several ETS family members are phosphorylated by MAPKs (Hill et al., 1993; Murakami et al., 2011; Petrovic et al., 2003) , and these modifications are known to affect their interaction with other transcription factors as well as their binding to DNA (Hollenhorst et al., 2011) . Future experiments will examine ETS factor phosphorylation downstream of Vegf/MAPK signaling and whether ETS factors functionally interact with other transcription factor families to establish arterial fate. Finally, we also demonstrate that a Vegf/ MAPK/ETS pathway regulates Notch4, suggesting that this pathway lies upstream of induction of Notch signaling in the arterial endothelium. Indeed, we observe reduced Notch-regulated gene expression and Notch-dependent reporter activity in embryos with reduced ETS activity. Interestingly, Notch4 is not as sensitive as Dll4 to ERG overexpression ( Figure 4B versus Figure 7C ), which may in part explain the delay in Notch4 expression during artery formation (Chong et al., 2011) .
RBPJk
In summary, we have uncovered a genetic pathway that integrates Vegf signaling, ETS-dependent transcriptional regulation, and the induction of one of the earliest, essential ligands for artery specification and Notch pathway activation, Dll4. This same pathway also regulates the expression of Notch4, an arterial-specific receptor for Dll4, and appears to initiate Notch signaling in the artery. These findings may provide insight into congenital defects in AV specification and maintenance and suggest approaches to direct endothelial cells toward the arterial lineage.
EXPERIMENTAL PROCEDURES
Bioinformatic Analyses, Cloning, Mutagenesis, Generation of Transgenic Mice, and Mouse Lines Used See Supplemental Experimental Procedures for details.
Mouse Experiments
All mouse protocols were approved by the Institutional Animal Care and Use Committee at UCSF and Harvard Medical School. Histology and in situ hybridization , ink injections (Krebs et al., 2004) , and CD31 immunofluorescence (Coultas et al., 2010) were performed as described elsewhere.
Electrophoretic Mobility Shift Assay DNA binding assays were performed as described previously . See Supplemental Experimental Procedures for details.
Cell Culture, Immunofluorescence, Luciferase Analysis, and ChIP Human umbilical vein endothelial cells (HUVECs) (ScienCell) and Bovine arterial endothelial cells (BAECs) (Lonza) were grown in endothelial media (ScienCell). BAECs were treated with 50 ng/ml recombinant Vegf-A 165 (R&D Systems), 0.5 mM SU5416 (Sigma), 20 mM U0126 (Invivogen), or 10 mM LY29004 (Cell Signaling) for 24 hr. Immunofluorescence of ERG and phalloidin was performed as described using ERG antibody (Santa Cruz, C-20, 1:100 dilution). pCS2-6xMYC-Etv2 has been described and pCMV-Sport6-ERG was from Open Biosystems (IMAGE clone 6052140). Cloning of pCS2-V5-ERG is described in Supplemental Experimental Procedures. Luciferase experiments were performed as described (Cheng et al., 2013) . Electroporation of HUVEC was performed using a Lonza 4D Nucleofector with the P5 Primary Cell Kit with 2.5 mg of expression construct and 0.5 mg of pmaxGFP. ChIP was performed using the Imprint Kit (Sigma) with 1 mg of antibody: RNA Pol II (mouse monoclonal, Sigma), ERG (rabbit polyclonal, Santa Cruz, C-20), V5 (mouse monoclonal, Invitrogen), or NICD (rabbit polyclonal, ChIP grade, Abcam). IgG (mouse, Sigma) was used as a negative control. Fold enrichment was calculated by determining the fold change of qPCR values for the specific antibody compared to IgG control. See Supplemental Experimental Procedures for primer sequences.
Zebrafish Experiments
Zebrafish protocols were approved by the Animal Care Committee at the University Health Network and UCSF. The following transgenic lines were utilized: Tg (kdrl:ras-mCherry) s896 , Tg(kdrl:GFP) s843 (Jin et al., 2005) , and Tg(EPV.Tp1-MmuHbb:EGFP) um14 (Parsons et al., 2009 
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qRT-PCR qRT-PCR was performed as before (Fish et al., 2008) . See Supplemental Experimental Procedures for details and primer sequences.
Western Blot
Western blotting was performed as described previously using ERG (rabbit polyclonal, Santa Cruz, C-20), Sin3a (Santa Cruz, AK-11), V5 (mouse monoclonal, Invitrogen), or GAPDH (mouse monoclonal, Santa Cruz) (mouse monoclonal, Abcam) antibodies. Cells were starved overnight and treated with 50 ng/ml recombinant Vegf-A 165 (R&D Systems) for 20 min before harvesting for subcellular fractionation, as previously described . HUVEC and HUAEC lysates were purchased from Sciencell.
Statistics
All graphs depict the mean ± SEM of at least three independent experiments unless otherwise indicated. Statistical significance was performed using a Student's t test, ANOVA, or c 2 test as appropriate. Dll4 in situ
SUPPLEMENTAL INFORMATION
GCCGAAAGAGTT GCCGAAAGAGTT * * * * * * * * * * * * * * * * * * * * * * * * * CCCGCGCTGGACGCTCGGATTCCGCTCGCTGCCTGGACTCAGAGCACAATTGCGTTTCCTGCGGGTTATTTTT CCCGCGCTGGACGCTCGGATTCCGCTCGCTGCCTGGACTCAGAGCACAATTGCGTTTCCTGCGGGTTATTTTT * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * GGCGTGGGAACGTGGGGAGCATGGCGGTGAGAAA GGCGTGGGAACGCGGGGAGTACGGCGGTGAGAAA GGCGTGGGAACGCGGGGAGCACGGCGGTGAGAAA * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * GGCCAGTGGTTGCCAGCGGCACTGACGGGCCCCT GGCT GGCC _ _ GAAGCTGCCAGCGCCGCTGACGGGCCCCT GAGGCTGCCAGCGCCGCTGACGGGCCTCT * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * _ _ _ * ** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * CTACTTTCTCCCCGCCTCTCCTATGCAGAGCTGAGGGATAGGGCACCCACGGGA GCTTGCTG ATTACCCACCTCTGGAG GCAGAACCCCTGAAT GGGCA CCAAAGGACCCCCTGCTCCCAGGGT ACAGAACCCCTTGCTCCCAG
GGAGCTGCGC * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ACAGAGGAAAAGGATATTTCAGTAGC ACAATTCTCACTTTGAAAAGGGGATAAAAGAGCCCAACACC ACAGAGGAAAAGGATATTTCAGCAGCACAACAATTCTCACTTTGAAAAGGAAAAAAGAAAACC ACAGAGGAAAAGGATATTTCACCAGCACAACAATTCTCACTTTGAAAAGGAAAAAGAAAAACC * * * * * * * * * * * * * TCCTGTATTTTACACCTTTTGCGAATTCCGCTCTTTTGGAAAGGGAATAATGGCTTTGGGATGTTGTTCTGAC TCCTGTATTTTACACCTTTCGCGAATTCCGCTCCTTTGGAAAGGGAATAATGGCTTTGGGATGTTGTTCTGAC TCCTGTATTTTACACCTTTTGCGAATTCCGCTCCTTTGGAAAGGGAATAATGGCTTTGGGATGTTGTTCTGAC
CATCACAGCCAAGAAGGACATTGGCCAGCCGTCA AGTCACAACTAAAGAGAGAGTTGG CAGCAGTCAACTCTCTCTGAATCAGGTTGGCTTTCTGAATCAGG TTCTCTGACCAAAGCCTCTTTCTG * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * (H) No defects in arteriovenous morphology in Ctnnb1 null (n=5) embryos were observed, as assessed by ink injection (as ink filled the entire dorsal aorta (arrows)) and H&E histology of serial cross-sections through the rostral and caudal planes of the dorsal aortae and cardinal veins. Dorsal aorta (arrow); cardinal vein (caret). Scale bars: 500 µm (B-H, whole-mount), 100 µm (C-H, sections and zoom ins). Figure S2 (Related to Figure 3 ): MEF2C and RBPJk bind to the F2 enhancer, and overexpression of NICD in the endothelium can drive F2 expression in the vein, while MEF2C is dispensable for early arterial Dll4 expression. (A) Recombinant MEF2C protein was used in an electrophoretic mobility shift assay (EMSA) with a radiolabelled double-stranded oligonucleotide representing the F2-6 MEF2 binding site. Lane 1 contains reticulocyte lysate without recombinant MEF2C (represented by a minus sign). MEF2C efficiently bound to the F2-6 MEF2 site (lane 2) and this binding was efficiently competed by an excess of the unlabeled wild type F2-6 MEF2 element (lane 3), but not by an excess of a mutant form of this site (lane 4). (B) The F2-lacZ enhancer was crossed into the Mef2c +/-background, and wild-type and homozygous mutant embryos were stained for X-gal at E8.5, 9.0, and E9.5. No difference in enhancer activity was observable in mutant embryos compared to wild-type (Mef2c +/+ ) littermates at early stages of vascular development (i.e. E8.5-E9.0) (n ≥ 5 for each genotype). The dorsal aorta is indicated by arrows. Scale bars = 500 µm (C) Expression of Dll4 mRNA was examined by in situ hybridization in Mef2c +/+ and Mef2c -/-embryos. No difference in expression was noted at E8.5 (n=3 for each genotype). Scale bars = 500 µm (D) NICD was over-expressed in the endothelium via Tie2-Cre-mediated activation of a R26 N1ICD allele. Whole-mount images (left; scale bar = 500 µm) and sections (right; scale bar = 100 µm) are shown. The presence of an arteriovenous malformation (AVM) is indicated by an asterisk and the dorsal aorta (arrow) and cardinal vein (caret) are also indicated. Expression of F2 was expanded into the cardinal vein in Notch over-expression embryos. (E) EMSA showing RBPJk binding to a probe corresponding to the F2-6 RBPJk site. Binding was competed by an excess of unlabeled wild-type but not RBPJk mutant probe. conserved ETS consensus (GGA(A/T)) sequences (red boxes). Murine F2 contains a total of 14 ETS sites, with five more non-conserved sites (blue boxes). The minimal 36-bp enhancer (F2-6) is highlighted (yellow box). Asterisks denote conserved nucleotides across all three species. (B) Recombinant ETS1 DNA-binding domain (DBD) was used in EMSA with radiolabelled probe encompassing a confirmed ETS-binding site from the Mef2c F7 enhancer. Lane 1 contains reticulocyte lysate lacking ETS1 DBD. ETS1 DBD bound the bona fide ETS-binding site in the control probe (Mef2c F7) (lane 2) and this specific binding was competed away by unlabeled control probe (lane 3), but binding was not competed by a control probe with a mutated ETS site (lane 4). Unlabeled probes corresponding to each of the potential ETS sites in the Dll4 F2 enhancer were used as competitors for ETS1 DBD binding to the control probe (lanes 5-18). The Dll4 F2 sites competed for ETS DBD binding to varying degrees. Probes encompassing ETS-B, ETS-D, ETS-H, ETS-I, ETS-J, and ETS-L competed most efficiently (lanes 8, 10, 13, 14, 15, 17, respectively) . In addition to the GGA(A/T) core, ETS-B and ETS-H possessed (or overlapped with) canonical ETS sites (cETS). cETS-1/ETS-B was a consistent competitor (lanes 5 and 8), and directly bound the ETS1-DBD (panel C), but cETS-2 (lane 6) and ETS-H (lane 13) did not compete consistently, and they did not bind the ETS1-DBD directly (data not shown). and Erg Δ Ex4/ Δ Ex4 (n=2) embryos (E9.5) were stained with PECAM antibodies and confocal microscopy was utilized to observe vascular patterning. The dorsal aorta (arrow) was present and morphologically normal in Erg knock-out embryos. Scale bars = 500 µm (wholemount) and 110 µm (zoom ins). (C) Section in situ hybridization at E8.5 reveals reduced Efnb2 mRNA in the dorsal aorta (arrows) in Erg knock out embryos (n=2) compared to wild-type littermates (n=2). Sections are counter-stained with nuclear fast red. Scale bar = 100 µm. (D) Histology of serial cross-sections through wild-type (n=3) and Erg knock-out embryos (E9.5) (n=2) did not reveal gross morphological defects in arteries or veins. Dorsal aorta (arrow); cardinal vein (caret). Scale bar = 100 µm. 
